You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Enpicom will initially offer separate solutions on its ImmunoGenomiX platform for research and clinical applications in oncology but seeks to expand into other disease areas.
In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.
The software, developed by researchers at the Ontario Institute for Cancer Research, uses machine learning methods to classify mutations as germline or somatic.
Participants tried to classify samples based on the epigenomic impact of cigarette smoke cessation and aerosol from modified- or reduced-risk products.
The computational method, called DeepCpG, is designed to tease out missing epigenetic marks and related DNA motifs in single-cell DNA methylation data.
Codexis has been using its CodeEvolver platform to engineer high-performance enzymes for next-generation sequencing and PCR for in vitro diagnostics.
Objectives for this year include building a network of ELIXIR beacons, developing new features and security measures, and partnering with data owners.
As part of the deal, scientists from Philips' Intellispace Genomics development team will relocate to NYMC's biotechnology incubator in Westchester County.
The newly minted company offers panel, whole-genome and whole exome sequencing, as well as bioinformatics analysis and reporting services to oncologists.
The curriculum will cover computer science and experimental biology courses and offer opportunities for students to contribute to faculty research projects.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.